Patents approved

RNS Number : 6271Q

Tissue Regenix Group PLC

05 August 2010

 



Tissue Regenix Group Plc

("Tissue Regenix" or the "Company")

Tissue Regenix granted two new patents in the U.S. and Australia

Tissue Regenix, a medical technology company focused on the development and commercialisation of acellular tissue replacement products to address the chronic global shortfalls in donor tissue availability, today announces the grant of two new patents in the U.S. and Australia relating to the Ultrasonic Modification of Matrices. 

These patents form part of the exclusive worldwide licence held by the company from the University of Leeds relating to its dCELL® Technology.

Antony Odell, Tissue Regenix Managing Director, said: "These patents augment our capacity to produce 'cell friendly' scaffolds and enhance our current intellectual property portfolio around our proprietary dCELL® Technology."

Ultrasonic Modification of Matrices is a method of utilizing ultrasonic energy so that the tissue can be rapidly recellularized once implanted in the patient.

Country                Patent No.                          Expiry Date

US                           7754232                                14/5/24

Australia              2004241775                         14/5/24

Enquiries:

Financial Dynamics
Ben Atwell / John Dineen	[phone]
Tissue Regenix Group plc
Antony Odell	[phone]
ZAI Corporate Finance Ltd John Depasquale /Sarang Shah	[phone]

About Tissue Regenix

Tissue Regenix was incorporated in May 2006 to commercialise the academic research of Professor Eileen Ingham and Professor John Fisher from the University of Leeds in the field of tissue decellularisation. Its dCELL® Technology comprises a patented process which removes cells and other components from human and animal tissue allowing it to be used without anti-rejection drugs to replace worn out or diseased body parts.

About dCELL® Technology

The process comprised within the dCELL® Technology involves the production of biological scaffolds created by taking a piece of human or animal tissue that is equivalent to the diseased or damaged body part which is being replaced, treating such tissue with a series of gentle chemical washes and then sterilising it. The end product is a scaffold which can be stored under normal conditions at room temperature like any synthetic medical device and, when it is implanted into the body, it repopulates with the patient's own cells using natural biological repair mechanisms.

Tissue Regenix's strategy is to continue to use its core dCELL® Technology as a platform to develop a range of products using the established medical device regulatory pathway to deliver solutions to unmet clinical needs. The three priority markets for the application of the technology are: Vascular (e.g. Vascular Patches); Cardiac (e.g. Heart Valves); and Orthopaedics (e.g. Meniscus).

 

END

 

 

MSCBSGDIDSGBGGU